Details
Stereochemistry | RACEMIC |
Molecular Formula | C19H22N2S.ClH.H2O |
Molecular Weight | 364.933 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
O.Cl.CN1CCCC(CN2C3=C(SC4=C2C=CC=C4)C=CC=C3)C1
InChI
InChIKey=TWEHDGPVRLPOEF-UHFFFAOYSA-N
InChI=1S/C19H22N2S.ClH.H2O/c1-20-12-6-7-15(13-20)14-21-16-8-2-4-10-18(16)22-19-11-5-3-9-17(19)21;;/h2-5,8-11,15H,6-7,12-14H2,1H3;1H;1H2
CNS Activity
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
75 mg 3 times / day multiple, oral Recommended Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: Page: p.729 |
unhealthy, 20-59 n = 33 Health Status: unhealthy Condition: schizophrenia Age Group: 20-59 Sex: F Population Size: 33 Sources: Page: p.729 |
Disc. AE: Agranulocytosis... AEs leading to discontinuation/dose reduction: Agranulocytosis (3%) Sources: Page: p.729 |
50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, 35 n = 1 Health Status: unhealthy Condition: depisssion Age Group: 35 Sex: F Population Size: 1 Sources: |
Disc. AE: Agranulocytosis... AEs leading to discontinuation/dose reduction: Agranulocytosis Sources: |
300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: Page: p.80 |
unhealthy, 37.1±1.5 n = 50 Health Status: unhealthy Condition: schizophrenia Age Group: 37.1±1.5 Sex: M+F Population Size: 50 Sources: Page: p.80 |
Disc. AE: Cycloplegia... AEs leading to discontinuation/dose reduction: Cycloplegia (4%) Sources: Page: p.80 |
900 mg multiple, oral Highest studied dose Dose: 900 mg Route: oral Route: multiple Dose: 900 mg Sources: Page: p.144 |
unhealthy n = 2 Health Status: unhealthy Condition: schizophrenia Population Size: 2 Sources: Page: p.144 |
|
25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Sources: Page: p.144 |
unhealthy n = 2 Health Status: unhealthy Condition: schizophrenia Population Size: 2 Sources: Page: p.144 |
Disc. AE: Jaundice... AEs leading to discontinuation/dose reduction: Jaundice Sources: Page: p.144 |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Agranulocytosis | 3% Disc. AE |
75 mg 3 times / day multiple, oral Recommended Dose: 75 mg, 3 times / day Route: oral Route: multiple Dose: 75 mg, 3 times / day Sources: Page: p.729 |
unhealthy, 20-59 n = 33 Health Status: unhealthy Condition: schizophrenia Age Group: 20-59 Sex: F Population Size: 33 Sources: Page: p.729 |
Agranulocytosis | Disc. AE | 50 mg 3 times / day multiple, oral Recommended Dose: 50 mg, 3 times / day Route: oral Route: multiple Dose: 50 mg, 3 times / day Sources: |
unhealthy, 35 n = 1 Health Status: unhealthy Condition: depisssion Age Group: 35 Sex: F Population Size: 1 Sources: |
Cycloplegia | 4% Disc. AE |
300 mg multiple, oral Recommended Dose: 300 mg Route: oral Route: multiple Dose: 300 mg Sources: Page: p.80 |
unhealthy, 37.1±1.5 n = 50 Health Status: unhealthy Condition: schizophrenia Age Group: 37.1±1.5 Sex: M+F Population Size: 50 Sources: Page: p.80 |
Jaundice | Disc. AE | 25 mg 3 times / day multiple, oral Studied dose Dose: 25 mg, 3 times / day Route: oral Route: multiple Dose: 25 mg, 3 times / day Sources: Page: p.144 |
unhealthy n = 2 Health Status: unhealthy Condition: schizophrenia Population Size: 2 Sources: Page: p.144 |
PubMed
Title | Date | PubMed |
---|---|---|
Changes in clinical trials methodology over time: a systematic review of six decades of research in psychopharmacology. | 2010 Mar 3 |
|
Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011 Jul 14 |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C66883
Created by
admin on Fri Dec 15 16:13:58 GMT 2023 , Edited by admin on Fri Dec 15 16:13:58 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID80977024
Created by
admin on Fri Dec 15 16:13:58 GMT 2023 , Edited by admin on Fri Dec 15 16:13:58 GMT 2023
|
PRIMARY | |||
|
AF6V3D768R
Created by
admin on Fri Dec 15 16:13:58 GMT 2023 , Edited by admin on Fri Dec 15 16:13:58 GMT 2023
|
PRIMARY | |||
|
C80675
Created by
admin on Fri Dec 15 16:13:58 GMT 2023 , Edited by admin on Fri Dec 15 16:13:58 GMT 2023
|
PRIMARY | |||
|
44154839
Created by
admin on Fri Dec 15 16:13:58 GMT 2023 , Edited by admin on Fri Dec 15 16:13:58 GMT 2023
|
PRIMARY | |||
|
6146-88-9
Created by
admin on Fri Dec 15 16:13:58 GMT 2023 , Edited by admin on Fri Dec 15 16:13:58 GMT 2023
|
PRIMARY | |||
|
m816
Created by
admin on Fri Dec 15 16:13:58 GMT 2023 , Edited by admin on Fri Dec 15 16:13:58 GMT 2023
|
PRIMARY | Merck Index |
ACTIVE MOIETY
SUBSTANCE RECORD